两年亏损3.07亿！麦济生物估值增近45倍

Core Viewpoint - Hunan Maijizhi Biotechnology Co., Ltd. (referred to as "Maijizhi") has submitted an application for listing on the Hong Kong Stock Exchange, with CICC as the exclusive sponsor. The company has been experiencing continuous losses but has seen its post-investment valuation increase nearly 45 times over the past eight years [1][2][9]. Company Overview - Established in 2016, Maijizhi is a clinical-stage biopharmaceutical company focused on addressing unmet medical needs in allergic diseases, autoimmune diseases, and other inflammatory and immune diseases. The company currently has no products on the market, with its core product MG-K10 being a long-acting anti-IL-4Rα antibody with "best-in-class" potential [5][6]. Product Pipeline - MG-K10 targets atopic dermatitis (AD), a chronic inflammatory skin disease with a significant global burden, affecting at least 230 million people. In China, the prevalence of AD has increased by 25.65% from 1990 to 2019, with approximately 36.09 million patients currently, including about 9.63 million with moderate to severe cases [5][6]. - In addition to MG-K10, Maijizhi has two other self-developed products in clinical stages: MG-014, targeting asthma and COPD, and MG-013, an anti-MASP-2 monoclonal antibody aimed at rare and inflammatory diseases [6][7]. Financial Performance - For the first three months of 2023, 2024, and 2025, Maijizhi reported revenues of 8.72 million, 24,000, and 0, respectively, with corresponding net losses of 253 million, 178 million, and 27.3 million. The company incurred significant R&D expenses of 166 million and 150 million in 2023 and 2024, leading to a total adjusted net loss of approximately 307 million over these two years [7][8]. - In Q1 2025, the company recorded no revenue and continued to incur losses with R&D expenses of 24.3 million [8]. Valuation Growth - The company's valuation has seen substantial growth over the years, starting from 58 million in early 2017 to 2.64 billion in May 2025, reflecting a nearly 45-fold increase [9][10]. IPO Fund Utilization - The funds raised from the IPO will be used for ongoing and planned clinical trials of the core product MG-K10, as well as for MG-014 and MG-013, along with other preclinical and discovery-stage assets [11].